Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Ann Oncol 2017; 28(6): 1368–1379 (doi: 10.1093/annonc/mdx108) In the original article, there were errors in Figure 3B and the accompanying legend. These have been corrected online as below. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumabAnnals of OncologyVol. 28Issue 6PreviewIpilimumab, an immune checkpoint inhibitor targeting CTLA-4, prolongs survival in a subset of patients with metastatic melanoma (MM) but can induce immune-related adverse events, including enterocolitis. We hypothesized that baseline gut microbiota could predict ipilimumab anti-tumor response and/or intestinal toxicity. Full-Text PDF Open Archive